Abstract
Coinciding in time with the expiration of the patent of enoxaparin and clopidogrel, a number of new antithrombotics (anticoagulants and antiplatelets with new mechanisms of action) have been developed or are still under development for both venous and arterial thromboembolic complications. The effect of antithrombotic drugs is a continuum where a fine tune assessment of the ischemic events that are intended to be prevented and bleeding complications derived naturally from the own mechanism of action of the administered agent is essential. This paper discusses relevant aspects of pivotal studies aimed to support the marketing authorisation application of new antithrombotics for the prophylaxis or treatment of venous thromboembolism on one hand, and arterial thromboembolism on the other hand (acute coronary syndromes and stroke and systemic embolic events in patients with atrial fibrillation). General methodological issues and tools to assess efficacy and safety parameters and problems encountered in the way they are measured and classified are discussed.
Keywords: Antithrombotics, clinical trials, guidelines, methodology, thromboembolism
Current Drug Discovery Technologies
Title:Clinical Drug Development in Thromboembolic Diseases: Regulatory and Methodological Approach
Volume: 9 Issue: 2
Author(s): Gonzalo Calvo-Rojas and Antonio Gomez-Outes
Affiliation:
Keywords: Antithrombotics, clinical trials, guidelines, methodology, thromboembolism
Abstract: Coinciding in time with the expiration of the patent of enoxaparin and clopidogrel, a number of new antithrombotics (anticoagulants and antiplatelets with new mechanisms of action) have been developed or are still under development for both venous and arterial thromboembolic complications. The effect of antithrombotic drugs is a continuum where a fine tune assessment of the ischemic events that are intended to be prevented and bleeding complications derived naturally from the own mechanism of action of the administered agent is essential. This paper discusses relevant aspects of pivotal studies aimed to support the marketing authorisation application of new antithrombotics for the prophylaxis or treatment of venous thromboembolism on one hand, and arterial thromboembolism on the other hand (acute coronary syndromes and stroke and systemic embolic events in patients with atrial fibrillation). General methodological issues and tools to assess efficacy and safety parameters and problems encountered in the way they are measured and classified are discussed.
Export Options
About this article
Cite this article as:
Calvo-Rojas Gonzalo and Gomez-Outes Antonio, Clinical Drug Development in Thromboembolic Diseases: Regulatory and Methodological Approach, Current Drug Discovery Technologies 2012; 9 (2) . https://dx.doi.org/10.2174/1570163811209020105
DOI https://dx.doi.org/10.2174/1570163811209020105 |
Print ISSN 1570-1638 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6220 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Prevention of Pre-eclampsia with the Use of Acetylsalicylic Acid and Low-molecular Weight Heparin – Molecular Mechanisms
Current Pharmaceutical Biotechnology Update on MDS Therapy: From Famine to Feast
Cardiovascular & Hematological Agents in Medicinal Chemistry ADAM10 as a Therapeutic Target for Cancer and Inflammation
Current Pharmaceutical Design A Case of Subdural Hematoma without Subarachnoid Hemorrhage Secondary to Rupture of Posterior Communicating Artery-infundibular Dilatation
Current Medical Imaging Genetic Bases of Progressive Supranuclear Palsy: The MAPT Tau Disease
Current Medicinal Chemistry miR-490-3p Alleviates Cardiomyocyte Injury via Targeting FOXO1
Protein & Peptide Letters Plasma VEGF and IL-8 Levels in Patients with Mixed Dyslipidaemia. Effect of Rosuvastatin Monotherapy or its Combination at a Lower Dose with Omega-3 Fatty Acids: A Pilot Study
Current Vascular Pharmacology Editorial [ Proteases and Phospholipases in CNS Disorders Guest Editor: Swapan K. Ray ]
CNS & Neurological Disorders - Drug Targets Cytokines and Hormones in the Regulation of Hypoxia Inducible Factor-1α (HIF-1α)
Cardiovascular & Hematological Agents in Medicinal Chemistry Ketamine and Glutamate Receptors: Potential Toxicity of General Anesthetics during Rapid Brain Development
Central Nervous System Agents in Medicinal Chemistry Respiratory Syncytial Virus is the Most Common Causative Agent of Viral Bronchiolitis in Young Children: An Updated Review
Current Pediatric Reviews Efficient Synthesis of 6-O-methyl-scutellarein from Scutellarin via Selective Methylation
Letters in Organic Chemistry Quantitative Analysis of Salicylic Acid and its Derivatives in Primulae radix by High Performance Liquid Chromatography-Diode Array Detection- Electrospray Ionization Mass Spectrometry (HPLC-DAD-ESI-MS) and Simultaneous Determination of Total Polyphenol Content (TPC)
Current Analytical Chemistry MMP Inhibitors in Cardiac Diseases: An Update
Recent Patents on Cardiovascular Drug Discovery Recent Patents in Cartilage Regeneration
Recent Patents on Regenerative Medicine Statins in Aortic Disease
Current Pharmaceutical Design The Cytochrome P450 2C19 Polymorphism Associated with Major Adverse Cardiovascular Events Risk in Kazak Patients Undergoing Percutaneous Coronary Intervention and Receiving Clopidogrel
Endocrine, Metabolic & Immune Disorders - Drug Targets Does Semantic Memory Impairment in Amnestic MCI with Hippocampal Atrophy Conform to a Distinctive Pattern of Progression?
Current Alzheimer Research Antiapoptotic Drugs: A Therapautic Strategy for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design Vascular C-Reactive Protein in the Pathogenesis of Coronary Artery Disease:Role of Vascular Inflammation and Oxidative Stress
Cardiovascular & Hematological Disorders-Drug Targets